We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    Daniel Pollyea | Acute Myeloid Leukemia | Colorado, United States
Previous Study | Return to List | Next Study

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03573024
Recruitment Status : Recruiting
First Posted : June 28, 2018
Last Update Posted : March 17, 2023
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This study aims to treat non-elderly adult patients, who were previously untreated for acute myeloid leukemia, using venetoclax and azacitidine.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Azacitidine Drug: Venetoclax Phase 2

Detailed Description:
This is a phase II study that seeks to treat patients ages 18-59 who have acute myeloid leukemia but have never been treated before. It will use venetoclax and azacitidine, and patients can receive up to four cycles of this medication. Depending on the level of recovery, patients will either be forced to come off study or have the option to continue the medication, receive maintenance therapy, or pursue an allogeneic stem cell transplant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients (Aged 18-59) With Acute Myeloid Leukemia
Actual Study Start Date : November 14, 2018
Estimated Primary Completion Date : June 25, 2023
Estimated Study Completion Date : June 2025

Arm Intervention/treatment
Experimental: Azacitidine and Venetoclax
Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
Drug: Azacitidine
On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.

Drug: Venetoclax
Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.

Primary Outcome Measures :
  1. Response Rate, measured by the European Leukemia Net definition: (CRMRD-+CR+CRi+MLFS) [ Time Frame: Study start date to study end date, or death, whichever comes first, up to 4 years ]
    The (CRMRD-+CR+CRi+MLFS) shows non-inferiority of venetoclax with azacitidine when compared with historical controls who received induction chemotherapy.

Secondary Outcome Measures :
  1. Incidence of Minimal Residual Disease (MRD) Negative Responses [ Time Frame: Study start date to study end date, or death, whichever comes first, up to 4 years ]
    Number of new cases of Complete Remission, Complete Remission with Incomplete Blood Count Recovery, or Morphologic Leukemia Free State. This will be measure by multi-dimensional flow cytometry with a sensitivity to 0.1%.

  2. Remission Duration [ Time Frame: Study start date to study end date, or death, whichever comes first, up to 4 years ]
    Remission Duration will be defined as the length of time a patient does not display leukemic blasts or extramedullary disease

  3. One Year Event Free Survival [ Time Frame: Study start date to study end date, or death, whichever comes first, up to 4 years ]
    Determined using Kaplan Meier survival analysis methods with 95% confidence intervals.

  4. Overall Survival [ Time Frame: Study start date to study end date, or death, whichever comes first, up to 4 years ]
    Overall Survival will be defined as the time from administration of the initial doses until death from any cause. Determined using Kaplan Meier survival analysis methods with 95% confidence intervals.

  5. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Study start date to study end date, or death, whichever comes first, up to 4 years ]
    Safety and tolerability analysis of azacitidine and venetoclax will be summarized by dose and severity as assessed by the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 and relationship to study drug.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

A subject will be eligible for study participation if he/she meets the following criteria within 28 days prior to the first day of therapy (bone marrow biopsy can be performed 28 days prior to the first day of therapy). Historical records are permitted per Investigator discretion.

  1. Subject must have confirmation of non-APL and AML by WHO criteria45
  2. Subject must have received no prior treatment for AML
  3. Age ≥18 years, ≤59 years
  4. Without clinical signs of active central nervous system disease
  5. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of ≤2
  6. Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula
  7. Subject must have adequate liver function as demonstrated by:

    • aspartate aminotransferase (AST) ≤ 3.0 × ULN*
    • alanine aminotransferase (ALT) ≤ 3.0 × ULN*
    • bilirubin ≤ 3.0 × ULN, unless due to Gilbert's syndrome* * Unless considered due to leukemic organ involvement
  8. Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug.
  9. Female subjects who are pre-menopausal and have not had a hysterectomy or oophorectomy must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting therapy; 2) throughout the entire duration of treatment; 3) during dose interruptions; and 4) for at least 90 days after discontinuation of therapy (last dose of study drug).
  10. Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed screening procedures.
  11. Subject must have adverse risk disease as defined by the European LeukemiaNet46 (Appendix B) 5.3.2 Exclusion Criteria

A subject will not be eligible for study participation if he/she meets any of the following criteria:

  1. Subject has received disease modifying treatment for myelodysplastic syndrome (MDS) or AML. ATRA given for clinical suspicion of APL will not be exclusionary and no washout will be required in this scenario.
  2. Subject is known to be positive for HIV. HIV testing is not required.
  3. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag-, anti-HBs+ and anti-HBc-) may participate
  4. Subject has received within 7 days prior to the first dose of study drug:steroid therapy for anti-neoplastic intent; strong and moderate CYP3A inhibitors; strong and moderate CYP3A inducers.
  5. Subject is informed that consumption of the following fruits is prohibited 3 days prior to the initiation of study treatment and throughout participation: grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit.
  6. Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:

    • New York Heart Association heart failure > class 2
    • Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia
  7. Subject has a malabsorption syndrome or other condition that precludes enteral route of administration
  8. Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)
  9. Subject has a history of other malignancies prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma of the breast or cervix uteri
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
    • Prostate cancer with no plans for therapy of any kind
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  10. Subject has a white blood cell count >25 × 10^9/L or absolute blast count of >50 10^9/L. Hydroxyurea and leukapheresis are permitted, if clinically indicated.
  11. Patients willing to receive intensive induction chemotherapy
  12. Pregnant and breastfeeding females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03573024

Layout table for location contacts
Contact: Constance Brecl 720-848-8084 constance.brecl@cuanschutz.edu

Layout table for location information
United States, Colorado
Universtiy of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Daniel Pollyea       daniel.pollyea@cuanschutz.edu   
Principal Investigator: Daniel Pollyea, MD         
Sponsors and Collaborators
University of Colorado, Denver
Layout table for investigator information
Principal Investigator: Daniel Pollyea, MD University of Colorado, Denver
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03573024    
Other Study ID Numbers: 18-0709.cc
First Posted: June 28, 2018    Key Record Dates
Last Update Posted: March 17, 2023
Last Verified: March 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Colorado, Denver:
Previously Untreated
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors